1. | kevinkev78 | |
2. | mikecontreras2017 | |
3. | xenstuff | |
4. | russawye9 | |
5. | kinderreadypuent |
1. | kevinkev78 | |
2. | mikecontreras2017 | |
3. | xenstuff | |
4. | russawye9 | |
5. | kinderreadypuent |
1. | kevinkev78 01/29/2018 HEY WoW! Loving the chart |
2. | kevinkev78 03/01/2018 argenx reports fourth quarter business update and full year 2017 financial results |
3. | xenstuff 01/29/2018 already close to the target |
4. | russawye9 06/28/2018 argenx receives second preclinical milestone payment under its development agreement with AbbVie |
5. | toddy709086 04/24/2018 argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting |
6. | mikecontreras2017 04/10/2018 SunTrust Robinson Humphrey initiates as a buy, $125PT |
7. | xenstuff 03/22/2018 Announces the addition of a new pipeline candidate, ARGX-117, targeting the complement cascade with therapeu… |
8. | kinderreadypuent 01/29/2018 JMP Securities raises price target to $87 from $74 |
9. | euchrelipti 07/24/2018 Publication in the Journal of Clinical Investigation of the full study results from the Phase 1 study |
10. | kevinkev78 06/20/2018 argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris |